AIM疫苗提交MRNA RSV疫苗供美国试验,目的是进入一个兴旺的全球市场。 AIM Vaccine submits mRNA RSV vaccine for U.S. trials, aiming to tap into a booming global market.

以香港为基地的一家主要疫苗公司AIM疫苗公司提交了其MRNA RSV疫苗,供美国临床试验之用。 AIM Vaccine, a leading Hong Kong-based vaccine company, has submitted its mRNA RSV vaccine for U.S. clinical trials. 在临床前试验中,疫苗的免疫水平高于现有RSV疫苗。 The vaccine showed higher immunity levels than current RSV vaccines in preclinical trials. 这可能会推动非洲免疫运动的国际扩张,预计到2030年全球抗逆转录病毒疫苗市场将达到167亿美元。 This could boost AIM's international expansion, with a growing global RSV vaccine market projected to reach $16.7 billion by 2030. 多家机构给予AIM疫苗“Buy”评级。 Multiple institutions have given AIM Vaccine a "Buy" rating.